Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGx-SELECT: Pharmacogenetics to Select Erbitux or Cisplatin in Head and Neck Cancer
NCT00881114Phase 2Withdrawn
- Sponsor
- Georgetown University
- Start
- Apr 2009
- Primary completion
- Jun 2009
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
A Phase 2 trial of cisplatin, cetuximab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Georgetown University. Planned start Apr 2009; status: withdrawn.
02
Drugs
cisplatincetuximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00881114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881114.